# 04_QA_REPORT.md

# Quality Assurance Report

---

# Identity

| Field | Value |
|-------|-------|
| QA Report ID | QA-PP-0235 |
| Population Package | PP-0235 |
| Title | Somatic Genetic Testing |
| Version | 1.0.0 |
| Review Status | PASS |

---

# Layer 1 — Content QA

| Criterion | Result |
|-----------|--------|
| Single educational question | PASS |
| Scope respected | PASS |
| Complete coverage | PASS |
| Internal consistency | PASS |
| Logical organization | PASS |
| Knowledge blocks complete | PASS |
| Clinical indications covered | PASS |
| Specimen considerations covered | PASS |
| Assay-selection concepts covered | PASS |
| Genomic alteration categories covered | PASS |
| Tumor-only boundary covered | PASS |
| Negative-result limitations covered | PASS |
| No overlap with adjacent Population Packages | PASS |

---

# Layer 2 — Clinical QA

| Criterion | Result |
|-----------|--------|
| Scientifically accurate | PASS |
| Consistent with ESMO/ASCO framework | PASS |
| Consistent with NCCN gastric-cancer context | PASS |
| Appropriate distinction between somatic and germline testing | PASS |
| Appropriate distinction between testing and interpretation | PASS |
| Appropriate explanation of tumor-only sequencing | PASS |
| Possible germline findings appropriately flagged | PASS |
| Confirmatory germline testing appropriately framed | PASS |
| Specimen/pre-analytic limitations appropriately explained | PASS |
| Assay-scope limitations appropriately explained | PASS |
| No unsupported treatment recommendation | PASS |
| No unsafe medical advice | PASS |

---

# Layer 3 — Educational QA

| Criterion | Result |
|-----------|--------|
| Plain language | PASS |
| Appropriate for patients | PASS |
| Learning objectives satisfied | PASS |
| Knowledge blocks follow a coherent sequence | PASS |
| Patient explanations included | PASS |
| Clinical importance included | PASS |
| Key concepts included | PASS |
| Common misconceptions addressed | PASS |
| Appropriate explanation of limitations | PASS |
| Appropriate explanation of clinical context | PASS |
| Encourages appropriate discussion with healthcare professionals | PASS |

---

# Layer 4 — Governance QA

| Criterion | Result |
|-----------|--------|
| CKO completed | PASS |
| Knowledge Passport completed | PASS |
| Evidence Package completed | PASS |
| Evidence traceability complete | PASS |
| Scope maintained | PASS |
| Knowledge Graph complete | PASS |
| Prerequisites defined | PASS |
| Related packages defined | PASS |
| Downstream packages defined | PASS |
| Versioning complete | PASS |
| Repository compliant | PASS |
| Four-artifact package complete | PASS |

---

# Clinical Safety Review

| Item | Result |
|------|--------|
| No individualized medical advice | PASS |
| No treatment recommendation from a mutation | PASS |
| No claim that tumor findings are automatically somatic | PASS |
| Appropriate germline-confirmation boundary | PASS |
| Appropriate explanation of negative results | PASS |
| Appropriate explanation of assay limitations | PASS |
| Appropriate distinction between testing and interpretation | PASS |
| Appropriate distinction between somatic and germline testing | PASS |
| No unsupported disease-specific testing algorithm | PASS |

---

# Educational Boundary Review

The Population Package successfully remains within the predefined educational boundary.

## Included

- definition of somatic genetic testing;
- gastric-cancer relevance;
- clinical indications;
- tumor specimen and adequacy;
- assay selection concepts;
- genomic alteration categories;
- targeted/panel/broader testing;
- tumor-only testing;
- possible germline implications;
- clinical contextualization;
- resistance/molecular evolution at conceptual level;
- limitations;
- patient education.

## Excluded

- detailed NGS/WGS/WES/RNA methodology;
- detailed variant interpretation;
- somatic oncogenicity classification;
- ACMG/ClinGen evidence criteria;
- detailed germline testing workflow;
- disease-specific biomarker testing;
- liquid biopsy/ctDNA methodology;
- treatment algorithms.

The **Atomic Knowledge Principle** has been preserved.

---

# Evidence Traceability Review

The major educational claims are traceable to the approved project evidence framework.

Particular attention was given to:

1. **Clinical indications for molecular testing**  
   ESMO/ASCO identifies diagnosis, prognosis, response prediction, disease/treatment monitoring and resistance mechanisms among molecular-testing applications. fileciteturn60file0

2. **Pre-analytic variables**  
   Tumor cellularity, nucleic-acid quality/quantity, archival age, collection, preparation, transport and storage are recognized as factors influencing test results. fileciteturn60file0

3. **Assay concepts and genomic alterations**  
   The source framework distinguishes specific-analyte testing, panel testing and broader genomic approaches and recognizes multiple genomic aberration types. fileciteturn60file0

4. **Tumor-only testing and germline implications**  
   Possible germline variants detected during somatic profiling may require additional work-up, including confirmatory germline testing and genetic counseling. fileciteturn60file0

---

# Package Completeness Review

| Required Artifact | Status |
|-------------------|--------|
| 01_CKO.md | COMPLETE |
| 02_Knowledge_Passport.md | COMPLETE |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | COMPLETE |
| 04_QA_REPORT.md | COMPLETE |

---

# Reviewer Notes

This Population Package establishes **Somatic Genetic Testing** as a foundational genomic-testing node within the gastric-cancer knowledge architecture.

The package deliberately positions somatic testing between:

**clinical question / tumor specimen**

and

**variant interpretation / clinical decision-making**.

The most important safety boundary is the distinction between a **tumor-detected variant** and a **confirmed somatic variant**. Tumor-only testing may identify findings that require additional germline evaluation.

The package also preserves the distinction between:

- testing;
- interpretation;
- classification;
- clinical actionability;
- treatment selection.

This prevents PP-0235 from duplicating PP-0106, PP-0109, biomarker-specific packages, liquid-biopsy/ctDNA packages, or treatment packages.

---

# Final Quality Decision

## PASS

PP-0235 satisfies the locked **Gold Population Package Specification v1.0**.

Approved as the official Population Package for:

> **PP-0235 — Somatic Genetic Testing**

Repository Status: **Ready**.

---

# Revision History

| Version | Date | Summary |
|----------|------|---------|
| 1.0.0 | 2026-08-08 | Revised Gold Release — expanded to match approved Gold package depth and structure |
